Search

Your search keyword '"Bendstrup, Elizabeth"' showing total 3 results
Start Over Author "Bendstrup, Elizabeth"
3 results on '"Bendstrup, Elizabeth"'

1. Pirfenidone and N-acetylcysteine (NAC) for the Treatment of Idiopathic Pulmonary Fibrosis (IPF): Exploratory Efficacy Results From the PANORAMA Study

Author

Behr, Juergen, primary, Bendstrup, Elizabeth, additional, Crestani, Bruno, additional, Günther, Andreas, additional, Olschewski, Horst, additional, Sköld, Magnus, additional, Wells, Athol, additional, Wuyts, Wim, additional, Koschel, Dirk, additional, Kreuter, Michael, additional, Wallaert, Benoit, additional, Tang, Hong, additional, Beck, JuergenKlaus, additional, and Albera, Carlo, additional

Published
2015
Full Text
View/download PDF

2. Acute exacerbation of fibrotic interstitial lung diseases.

Author

Hoyer N, Bendstrup E, Davidsen JR, Lund TK, and Shaker SB

Subjects
Humans, Glucocorticoids therapeutic use, Palliative Care, Lung Diseases, Interstitial diagnostic imaging, Lung Diseases, Interstitial therapy, Idiopathic Pulmonary Fibrosis diagnostic imaging, Idiopathic Pulmonary Fibrosis therapy, Heart Failure
Abstract

Acute exacerbation of idiopathic pulmonary fibrosis (AE-IPF) and other fibrotic interstitial lung diseases (AE-ILD) is defined by significant acute respiratory worsening and new widespread alveolar damage. This review summarises the current knowledge of diagnosis and treatment of these events. The diagnosis of AE-IPF and AE-ILD is based on typical HRCT findings of new and bilateral ground glass opacification and/or consolidation, and exclusion of fluid overload or cardiac failure. Treatment relies, despite low quality of evidence, on glucocorticoid in addition to supportive and palliative treatment. Despite treatment, the prognosis is poor, with a median survival of 2-4 months.

Published
2023

3. The case of methotrexate and the lung: Dr Jekyll and Mr Hyde.

Author

Cottin V, Bendstrup E, Bonniaud P, Nasser M, Spagnolo P, Valenzuela C, and Kolb M

Subjects
Humans, Lung diagnostic imaging, Methotrexate adverse effects
Abstract

Competing Interests: Conflict of interest: V. Cottin has received fees for consultancy from Actelion, Boehringer Ingelheim, Bayer, Biogen Idec, GSK, MSD, Novartis, Roche, Sanofi and Galapagos; has received lecture fees from Actelion, Boehringer Ingelheim, Novartis, Roche and Sanofi; has received reimbursement for travel to medical meetings from Actelion, Boehringer Ingelheim and Roche; has received fees for development of educational presentations from Boehringer Ingelheim; has acted as a member of an adjudication committee for Gilead; has received grants to his institution from Boehringer Ingelheim and Roche; and has acted as a member of data and safety monitoring boards for Promedior, Celgene and Galecto. Conflict of interest: E. Bendstrup has nothing to disclose. Conflict of interest: P. Bonniaud has nothing to disclose. Conflict of interest: M. Nasser has nothing to disclose. Conflict of interest: P. Spagnolo has nothing to disclose. Conflict of interest: C. Valenzuela has nothing to disclose. Conflict of interest: M. Kolb has received grants and personal fees from Roche, Boehringer Ingelheim, GSK, Gilead, Prometic (now Liminal Biosciences) and Pieris; grants from Avalyn; and personal fees from AstraZeneca, Novartis, Cipla, Bluefin Biomedicine, Algernon and Medscape

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results